[144] Tarsus Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Tarsus Pharmaceuticals (TARS) notice shows a proposed sale under Rule 144 of 6,000 common shares through Merrill Lynch, planned for 09/24/2025. The filing reports an aggregate market value of $332,208.38 for the shares and a company share count of 42,214,106, meaning the blocks represent a small fraction of outstanding stock. The shares were acquired in a private placement on 01/13/2017 and were paid for in cash. The filing also discloses a prior sale of 6,000 shares by the same trust on 08/11/2025 for $300,000. The filer certifies no undisclosed material adverse information and includes the standard Rule 10b5-1 notice language.

Insights

Securities Analyst

TL;DR: Small, non-material insider sale; limited investor impact.

The Form 144 records a proposed sale of 6,000 shares valued at roughly $332k, representing about 0.014% of the reported 42.2 million shares outstanding. The shares were originally acquired in a 2017 private placement and paid for in cash, indicating no financing or complex consideration. A near-term sale by the related trust occurred on 08/11/2025 for $300k, which suggests the filer is actively liquidating a modest position. Given the size relative to outstanding shares, this filing is unlikely to be material to valuation or market dynamics.

Corporate Governance Expert

TL;DR: Routine disclosure; standard certifications and no indication of undisclosed adverse information.

The notice includes the required representation that the seller is unaware of any material nonpublic information and references Rule 10b5-1 planning language. The transaction traces to a private placement date in 2017 and a cash payment, which simplifies ownership history. There are no signs of unusual timing, related-party complexities, or omissions in the form’s disclosed fields. From a governance perspective, this is a standard, compliant filing without governance red flags.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	MERRILL LYNCH 520 NEWPORT CENTER DRIVE 20TH FLOOR NEWPORT BEACH CA 92660	6000	332208.38	42214106	09/24/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	01/13/2017	PRIVATE PLACEMENT	TARSUS PHARMACEUTICALS INC			6000	01/13/2017	CASH

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
BOBAK AZAMIAN LIVING TRUST 15440 LAGUNA CANYON ROAD SUITE 160 IRVINE CA 92618	COMMON	08/11/2025	6000	300000

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for TARS disclose?

The Form 144 discloses a proposed sale of 6,000 common shares via Merrill Lynch, with an aggregate market value of $332,208.38, planned for 09/24/2025.

When were the shares being sold originally acquired?

The shares were acquired in a private placement on 01/13/2017 and payment was made in cash.

Has the filer sold any shares recently?

Yes. The filing reports a sale by the same trust of 6,000 shares on 08/11/2025 for $300,000.

How material is this sale relative to Tarsus outstanding shares?

The filing lists 42,214,106 shares outstanding; the 6,000-share block is roughly 0.014% of that total, a de minimis amount.

Does the Form 144 indicate any undisclosed adverse information?

The filer certifies they do not know of any material adverse information not publicly disclosed; no contrary information is provided in the form.